Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Death/intubation 25% primary Improvement Relative Risk ARDS 73% c19early.org/c Tan et al. Vitamin C for COVID-19 LATE TREATMENT Is late treatment with vitamin C+diammonium glycyrrhizinate beneficial for COVID-19? Retrospective 161 patients in China Lower progression with vitamin C+diammonium glycyrrhizinate (p=0.002) Tan et al., QJM, doi:10.1093/qjmed/hcab184 Favors vitamin C Favors control
Efficacy of diammonium glycyrrhizinate combined with vitamin C for treating hospitalized COVID-19 patients: a retrospective, observational stud
Tan et al., QJM, doi:10.1093/qjmed/hcab184
Tan et al., Efficacy of diammonium glycyrrhizinate combined with vitamin C for treating hospitalized COVID-19 patients: a.., QJM, doi:10.1093/qjmed/hcab184
Jul 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
PSM retrospective 207 hospitalized patients in China, 46 treated with diammonium glycyrrhizinate and vitamin C, showing lower risk of ARDS with treatment.
risk of death/intubation, 24.5% lower, RR 0.75, p = 0.74, treatment 1 of 46 (2.2%), control 14 of 115 (12.2%), NNT 10.0, odds ratio converted to relative risk, primary outcome.
risk of ARDS, 73.3% lower, RR 0.27, p = 0.002, treatment 7 of 46 (15.2%), control 41 of 115 (35.7%), NNT 4.9, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tan et al., 26 Jul 2021, retrospective, China, peer-reviewed, 7 authors, this trial uses multiple treatments in the treatment arm (combined with diammonium glycyrrhizinate) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
Abstract: Page 1 of 30 1 Efficacy of diammonium glycyrrhizinate combined with vitamin C for treating hospitalized 2 COVID-19 patients: a retrospective, observational study 3 4 Ruoming Tan1, Xiaogang Xiang2, Wei Chen3, Zhitao Yang4, Weiguo Hu5, Hongping Qu1*, Jialin 5 Liu1* 6 7 1 Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of 8 Medicine, Shanghai, 200025, China; 2 Department of Infectious Diseases, Ruijin Hospital, 9 Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China; 3 Department of 10 Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of 11 Medicine, Shanghai, 200025, China; 4 Department of Emergency, Ruijin Hospital, Shanghai Jiao 12 Tong University School of Medicine, Shanghai, 200025, China; 5 Department of Surgery, Ruijin 13 Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. 14 15 *Correspondence: 16 Jialin Liu*, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, 17 China, Email:ljl11243@rjh.com.cn, Phone: +86 21 53305091, Fax: +86 21 54500671. 18 Hongping Qu*, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 19 200025, China, Email:hongpingqu0412@hotmail.com. 20 21 22 23 24 25 26 27 28 29 30 © The Author(s) 2021. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oup.com 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Manuscripts submitted to QJM: An International Journal of Medicine Manuscripts submitted to QJM: An International Journal of Medicine 31 Abstract: 32 Background: The current global coronavirus disease 2019 (COVID-19) pandemic caused by severe 33 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has shown limited responses to medical 34 treatments. 35 Aims: To observe the effect of combination treatment of giammonium glycyrrhizinate and vitamin 36 C (DV)on the prognoses of patients with COVID-19. 37 Methods: This retrospective observational study recruited 207 COVID-19 patients from Tongji 38 Hospital,patients were assigned to DV and non-DV groups on the basis of the DV treatment. To 39 make the results more credible, a propensity-score matching (PSM) approach was adopted at a 1:3 40 ratio to determine the participants. Logistic analysis was used to assess the effect of DV therapy in 41 the progress of COVID-19. 42 Results: In the DV group, the new onset incidence rate of acute respiratory distress syndrome 43 (ARDS) after admission was clearly lower than that in the non-DV group (DV vs non-DV groups, 44 15.2% vs 35.7%; P=0.002). Compared with the non-DV group, the DV group showed fewer new 45 onset of complications (such as ARDS, acute liver injury and acute myocardial injury) (DV vs non- 46 DV groups,19.6% vs 46.1%; P=0.000). Moreover, DG+VC may help to recover the count of NK 47 cells and decrease the level of sIL-2R. 48 Conclusions: DG+VC might be a promising candidate for preventing the deterioration of COVID- 49 19 patients, which is worthy to be studied in large and perspective..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit